In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties.<\/p>\n
This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition, as amended and supplemented.<\/p>\n
Names of the companies and groups concerned:<\/strong><\/p>\n Nature of the operation<\/strong><\/p>\n Economic sectors concerned<\/strong><\/p>\n Deadline for interested third parties to submit their observations<\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council received notification of an economic concentration operation concerning the exclusive takeover by the company \u201cSubstipharm SAS\u201d of the assets and rights related to the pharmaceutical products \u201cRilutek\u201d and \u201cSabril\u201d held by the company \u201cSanofi SA\u201d.<\/p>\n \u201cSubstipharm SAS\u201d<\/strong> is a simplified joint-stock company under French law, with its registered office at 24, rue Erlanger, 75016 Paris, France, registered with the Paris Trade and Companies Register under number 480 064 385. \u201cSubstipharm SAS\u201d is active in the marketing of pharmaceutical and biological products.<\/p>\n \u201cSanofi SA\u201d<\/strong> is a French public limited company, with its registered office at 46, avenue de la Grande Arm\u00e9e, 75017 Paris, France, registered with the Paris Trade and Companies Register under number 395 030 844. \u201cSanofi SA\u201d is engaged in research, development, manufacturing, and marketing of health solutions.<\/p>\n <\/p>\n Done in Rabat, July 27, 2026<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition, as amended and supplemented. Names of the companies and groups concerned: The acquirer: the company \u201cSubstipharm SAS\u201d; The target: The assets and rights related to the pharmaceutical products \u201cRilutek\u201d and \u201cSabril\u201d held by the company \u201cSanofi SA\u201d. Nature of the operation Acquisition of asset elements. Economic sectors concerned Pharmaceutical sector. Deadline for interested third parties to submit their observations 10 days from the date of publication of this press release, i.e. August 6, 2026. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council received notification of an economic concentration operation concerning the exclusive takeover by the company \u201cSubstipharm SAS\u201d of the assets and rights related to the pharmaceutical products \u201cRilutek\u201d and \u201cSabril\u201d held by the company \u201cSanofi SA\u201d. \u201cSubstipharm SAS\u201d is a simplified joint-stock company under French law, with its registered office at 24, rue Erlanger, 75016 Paris, France, registered with the Paris Trade and Companies Register under number 480 064 385. \u201cSubstipharm SAS\u201d is active in the marketing of pharmaceutical and biological products. \u201cSanofi SA\u201d is a French public limited company, with its registered office at 46, avenue de la Grande Arm\u00e9e, 75017 Paris, France, registered with the Paris Trade and Companies Register under number 395 030 844. \u201cSanofi SA\u201d is engaged in research, development, manufacturing, and marketing of health solutions. Done in Rabat, July 27, 2026<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-48314","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n